A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
Vinge has advised Flat Capital in connection with its rights issue, which provides Flat Capital with proceeds of approximately SEK 153 million before deduction of transaction costs.
Pursuant to the agreement, SBB Residential Property AB will issue SEK 2.36 billion of preference shares to MSREI. The preference shares will be issued by an entity to be named SBB Residential Property AB forming a new group within SBB.
Axel Johnson AB, through its wholly-owned subsidiary, AxMedia AB, has made a public mandatory offer for all shares in Dustin Group AB (publ). The offer values all shares in Dustin at approximately SEK 3.2 billion.
Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 240 million before issue costs.
Bergs Timber AB (publ) (“Bergs”) has today acquired all shares in Hedlunda Holding AB (“Hedlunda”). Hedlunda is a state-of-the-art manufacturer of wooden furniture and components with production facilities in Sweden (Lycksele) and Poland (Skoczów).
Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.
Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.
ACQ Bure AB, a Swedish acquisition company (Special Purpose Acquisition Company) listed on Nasdaq Stockholm and Yubico AB have signed a merger agreement and adopted a joint merger plan to combine ACQ and Yubico.
Vinge has advised CTEK AB (publ) on a fully guaranteed rights issue, which will provide CTEK with issue proceeds of approximately SEK 350 million before deduction of transaction costs.
Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.
